半年内接连官宣即将控股派林生物与山东药玻,国药集团正以前所未有的速度整合产业链要素,释放出什么信号?撰文|Erin6月24日下午收盘后,一纸“详式权益变动报告书”,让上市公司山东药玻挂上“央”字头距离落定更近一步。24.45亿元自有资金、拿下实控权,仅半年时间里,这已经是国药集团第二次对上市公司下手。仅在半个月前,国药集团旗下中国生物官宣签署框架协议,拟收购派林生物21.03%股份,即将完成对这家...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.